Omalizumab

BATCH NUMBER: To be announced

334,00 €

Minimum order quantity: 7

Therapeutic Omalizumab antibody from the original Xolair ® commercial drug

Out of stock

Drug Aliquots On Demand

  • Commercial drug sourced worldwide
  • Delivery within 2-4 weeks​*
  • Excipients & Buffer: as original drug product
  • Quantity: minimum order quantity required​

*Subject to availability and market fluctuations.

Request For Quotation

Product specifications:​

  • Product Concentration 150 mg/mL
  • Volume per vial 40 µL
  • Quantity per vial 6 mg
  • Batch Number to be announced
  • Storage Temperature 2-8 °C / -80 °C
Our products are for research use only. The “therapeutic expiration date” implies expiry date for patient adminstration and is not applicable to the shelf life of the aliquot. Aliquot storage at -86°C ensures fully functional molecules even after the mentioned expiry date

Product Information:

Evidentic offers repackaged finished pharmaceutical products (e.g RMP/RLD). We refer to the repackaged RMP/RLD products synonymously as drug aliquots or aRMP, or short: aliquots.

We offer batches of original drug aliquots in low-binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.

As ‘raw material’ for the production of drug aliquots, Evidentic sources RMP from the European (EU) market. As a licensed pharmaceutical wholesaler, Evidentic is committed to Good Distribution Practice (GDP) compliance with respect to the procurement, storage and shipment of RMP.
Drug aliquots are manufactured by repackaging RMP in a qualified laboratory. The aliquotation process is performed under a quality and manufacturing agreement between Evidentic and the contract manufacturer. Repackaging of RMP includes the following steps: opening the secondary and primary RMP containers and transferring the specified volumes of RMP into an Eppendorf 0.5 ml low-binding (or similar) tube. If the RMP is a lyophilized powder and not a highly concentrated solution, reconstitute the RMP according to the original manufacturer’s instructions and then aliquot as a highly concentrated solution.
For identification purposes, drug aliquots are labeled with the date of aliquoting, the original lot number of the RMP, the original expiration date of the RMP, the name of the active ingredient (INN), and a unique identification code.
Immediately after aliquoting, drug aliquots are stored at either 2-8 °C or -86 °C for long-term storage. All drug aliquots stored at 2-8 °C are transferred to -86 °C at least two weeks before the expiration date of the original RLD/RMP is reached. Further quality or functional testing are not performed on the drug aliquots.  

Target

Class of molecule

Isotype

Host cells

Chinese hamster ovary (CHO) cells

Prepared from

Xolair®

Therapeutic Area

Therapeutic Indications

Mechanism of Action (MoA)

Omalizumab binds to IgE and prevents binding of IgE to Fc-RI (high-affinity IgE receptor) on basophils and mast cells, thereby reducing the amount of free IgE that is available to trigger the allergic cascade. Treatment of atopic subjects with Omalizumab resulted in a marked down-regulation of Fc-RI receptors on basophils. Treatment with Xolair inhibits IgE-mediated inflammation, as evidenced by reduced blood and tissue eosinophils and reduced inflammatory mediators, including IL4, IL-5, and IL-13 by innate, adaptive and non-immune cells.

Pharmacotherapeutic group​​

Drugs for obstructive airway diseases, other systemic drugs forobstructive airway diseases

List of Excipients​

Sucrose
L-histidine
L-histidine hydrochloride monohydrate
Polysorbate 20

Not looking for Omalizumab?

Search our therapeutic molecules product database

Evidentic GmbH
Am Mühlenberg 10

14476 Potsdam | Germany

+49 (0) 30 959 99 8831
info@evidentic.com

Cookie Preferences

Linkedin Youtube Facebook Twitter Instagram